Also, studies demonstrated that cyclin D-CDK4 kinase destabilized PD-L1 via Cullin3SPOP to control cancer immune surveillance and revealed the potential combination of CDK4/6 inhibitors and PD-1/PD-L1 blockade to enhance therapeutic efficacy for human cancers 79. Here, CDK4 is linked to cancer.